ASCO 2026: A revolution in pancreatic cancer

BioPharma DiveRallyBio tries again for reverse merger, this time with Avenzo

Endpoints NewsThe cost of a PRV is twice as high as it was three years ago — and it’s likely to stay that way

Endpoints NewsEpigenetic editing shows promise against chronic hep B infections

FierceBiotechASCO, Ryght AI team up for breast cancer trial site selection

Clinical OMICsSMArT Platform Improves Safety and Efficiency of CRISPR Editing in HSPCs

Clinical OMICsPancreatic Cancer Drug Doubles Survival While Reducing Side Effects

Endpoints NewsShionogi wins US approval for first pill to prevent Covid following exposure

Endpoints News#ASCO: Lilly's plenaries; Incyte's frontline data in lymphoma

BioPharma DiveServier buys into muscular dystrophy with potentially $2.7B deal

BioWorldASCO 2026: A revolution in pancreatic cancer

BioWorldBiggest gainers and losers for May 25-29, 2026

Endpoints NewsAgios licenses Oscotec drug; CEPI funds three potential Ebola vaccines